Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ortho Evra, a new contraceptive patch.

Brigitte L Sicat1

  • 1Department of Pharmacy, Virginia Commonwealth University, School of Pharmacy, Smith Building, Room 437, 410 North 12th Street, P.O. Box 980533, Richmond, VA 23298-0533, USA.

Pharmacotherapy
|April 12, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Processes and Metrics to Evaluate Faculty Practice Activities at US Schools of Pharmacy.

American journal of pharmaceutical education·2016
Same author

A collaboration among health sciences schools to enhance faculty development in teaching.

American journal of pharmaceutical education·2014
Same author

Best practices for implementing team-based learning in pharmacy education.

American journal of pharmaceutical education·2013
Same author

New therapeutic options for the management of diabetes.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists·2007
Same author

Development of a competency-based assessment process for advanced pharmacy practice experiences.

American journal of pharmaceutical education·2006
Same author

Newer insulin therapies for management of type 1 and type 2 diabetes mellitus.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists·2006
Same journal

Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

Pharmacotherapy·2026
Same journal

Response to Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

Pharmacotherapy·2026
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
See all related articles

The Ortho Evra transdermal patch offers pregnancy prevention efficacy comparable to oral contraceptives. However, it presents unique side effects like application-site reactions and potential reduced effectiveness in women over 90 kg.

Area of Science:

  • Contraception
  • Dermatology
  • Pharmacology

Background:

  • Ortho Evra represents the first transdermal contraceptive patch for pregnancy prevention.
  • Established oral contraceptives (OCs) serve as a benchmark for hormonal birth control efficacy and safety.

Purpose of the Study:

  • To evaluate the efficacy and safety of the Ortho Evra transdermal patch.
  • To compare Ortho Evra's performance against established oral contraceptives.

Main Methods:

  • Comparative clinical trials assessing pregnancy prevention.
  • Adverse event monitoring and reporting.
  • Evaluation of patch adherence and user compliance.

Main Results:

  • Ortho Evra demonstrated comparable efficacy to oral contraceptives (Mercilon, Triphasil).

Related Experiment Videos

  • Common adverse effects included breast symptoms, headache, and application-site reactions.
  • Patch detachment occurred in approximately 5% of subjects; 2% withdrew due to irritation.
  • Efficacy may be reduced in women weighing over 90 kg.
  • Compliance was higher with the patch compared to oral contraceptives in trials.

    • Conclusions:

    • The transdermal contraceptive patch is a viable alternative to oral contraceptives with similar efficacy.
    • Application-site reactions and potential weight-based efficacy differences require consideration.
    • Further research is needed to confirm long-term safety and advantages over existing methods.